



# Nitrogen dioxide and mortality: review and meta-analysis of long-term studies

Annunziata Faustini<sup>1</sup>, Regula Rapp<sup>2</sup> and Francesco Forastiere<sup>1</sup>

**Affiliations:** <sup>1</sup>Dept of Epidemiology, Regional Health Service, Lazio Region, Rome, Italy. <sup>2</sup>Swiss Tropical and Public Health Institute, Basel, Switzerland.

**Correspondence:** Annunziata Faustini, Dept of Epidemiology, Regional Health Service, Lazio Region, V. S. Costanza 53, 00198 Rome, Italy. E-mail: a.faustini@deplazio.it

**ABSTRACT** Exposure to ambient nitrogen dioxide (NO<sub>2</sub>) has been linked to increased mortality in several epidemiological studies but the question remains of whether NO<sub>2</sub> is directly responsible for the health effects or is only an indicator of other pollutants, including particulate matter. The aim of the present review was to provide pooled estimates of the long-term effects of NO<sub>2</sub> on mortality, which are potentially useful for health impact assessment.

We selected 23 papers, published from 2004 to 2013, evaluating the relationship between NO<sub>2</sub> and mortality, also including an assessment of the effect of particulate matter exposure. A random-effects meta-analysis was carried out on 19 studies.

The pooled effect on mortality was 1.04 (95% CI 1.02–1.06) with an increase of 10 µg·m<sup>-3</sup> in the annual NO<sub>2</sub> concentration and 1.05 (95% CI 1.01–1.09) for particulate matter <2.5 µm in diameter (PM<sub>2.5</sub>) (10 µg·m<sup>-3</sup>). The effect on cardiovascular mortality was 1.13 (95% CI 1.09–1.18) for NO<sub>2</sub> and 1.20 (95% CI 1.09–1.31) for PM<sub>2.5</sub>. The NO<sub>2</sub> effect on respiratory mortality was 1.03 (95% CI 1.02–1.03) and 1.05 (95% CI 1.01–1.09) for PM<sub>2.5</sub>. Four bipollutant analyses with particulate matter and NO<sub>2</sub> in the same models showed minimal changes in the effect estimates of NO<sub>2</sub>.

There is evidence of a long-term effect of NO<sub>2</sub> on mortality as great as that of PM<sub>2.5</sub>. An independent effect of NO<sub>2</sub> emerged from multipollutant models.



@ERSpublications

Any health impact assessment overlooking NO<sub>2</sub> would neglect some adverse effects of today's air pollution mixture <http://ow.ly/sPKsR>

---

This article has supplementary material available from [erj.ersjournals.com](http://erj.ersjournals.com)

Received: July 05 2013 | Accepted after revision: Dec 19 2013 | First published online: Feb 20 2014

Conflict of interest: None declared.

Copyright ©ERS 2014

## Introduction

The long-term effects on mortality of exposure to nitrogen dioxide (NO<sub>2</sub>) were assessed in the World Health Organization (WHO) Air Quality Guidelines in 2005 [1] and the overall evidence was considered limited, given the small number of studies available. Neither the development of chronic diseases nor lung cancer was clearly associated with NO<sub>2</sub> in any of the studies taken into consideration in the 2005 WHO report. However, short-term mortality studies, studies of the impairment of lung function growth in children and investigations of recurrent respiratory problems all suggested a NO<sub>2</sub> effect. Recent documents on traffic exposure from the American Thoracic Society [2] and the Health Effects Institute [3] considered NO<sub>2</sub>, among other traffic-related pollutants, and concluded that there is evidence suggesting that these pollutants have a causal role in mortality and the development of chronic respiratory diseases.

The recent review of the health effects of air pollution by a WHO working group (Review of Evidence on Health Aspects of Air Pollution (REVIHAAP)) [4] evaluated the most recent studies on long-term exposure to NO<sub>2</sub> and both natural (non-accidental)/total and cause-specific mortality. The question of whether NO<sub>2</sub> is directly responsible for the health effects or is only an indicator of other pollutants was specifically considered, including particulate matter and specific constituents such as metals, polycyclic aromatic hydrocarbons and other organic matter. The conclusion was that it is difficult “to judge the independent effects of NO<sub>2</sub> in the long-term studies because, in those investigations, the correlations between concentrations of NO<sub>2</sub> and other pollutants are often high, so that NO<sub>2</sub> might represent a mixture of traffic-related pollutants. In this case, chamber studies do not apply and toxicological evidence is limited. However, some epidemiological studies do suggest associations of long-term NO<sub>2</sub> exposures with respiratory and cardiovascular mortality and with children’s respiratory symptoms and lung function that were independent of [particulate matter] mass metrics. As with the short-term effects, NO<sub>2</sub> in these studies may represent other constituents. Despite this, the mechanistic evidence, particularly on respiratory effects, and the weight of evidence on short-term associations suggest a causal relationship.” In other words, the WHO working group suggested that the response to the causality question cannot be derived only from the epidemiological studies but requires the integration of exposure science, toxicology and human studies.

At the time of the REVIHAAP project, a quantitative systematic review of the long-term effects on mortality of NO<sub>2</sub> was not available. A subsequent review by HOEK *et al.* [5], considering the association between several pollutants and long-term mortality, showed a significant association of all-cause mortality with NO<sub>2</sub> in 15 longitudinal studies. Their work did not permit comparison of the effects of NO<sub>2</sub> with those of other pollutants, namely particulate matter, when the same studies were considered or when the results of the multipollutant models were available.

To contribute to the discussion of the role of NO<sub>2</sub> from an epidemiological perspective and to provide pooled estimates of the long-term effects of NO<sub>2</sub> on mortality, which are potentially useful for assessing the health impact of air pollution, we systematically examined the studies that investigated the long-term effects on mortality of both outdoor NO<sub>2</sub> and particles in the same population, and carried out a meta-analysis of both NO<sub>2</sub> and particulate matter effects.

## Methods

### Systematic review

The search strategy focused on studies reporting NO<sub>2</sub> (or nitrogen oxides (NO<sub>x</sub>)) effects on total and specific-cause mortality. The databases PubMed, Web of Science and LUDOK were searched. The search was restricted to the period from January 2004 to January 2013 and to studies in humans. Search terms were “nitrogen dioxide” (as “nitrogen dioxide/adverse effects” Medical Subject Headings in PubMed and as “nitrogen oxides” in LUDOK), together with “cohort study” or “case-control study”, and “mortality”, “cardiovascular mortality” and “respiratory mortality”.

Articles were included if long-term effects on natural/total or specific (cardiovascular or respiratory) mortality were assessed and the estimates of association with the pollutants were reported; the exposure needed to have been measured as at least an annual mean concentration in the study area. Papers were excluded when short-term effects were estimated, no health effect was measured, incidence or prevalence was assessed, no original data were analysed or, finally, when no control for confounding due to individual factors was carried out. Reviews and methodological papers were excluded as well. Studies carried out on groups restricted to at-risk people were, however, not excluded.

The first screening of the papers was carried out by checking the titles and abstracts. The texts of the remaining papers were read in full, so as to select those that also included effect estimates for particulate matter <10 µm in diameter (PM<sub>10</sub>) or PM<sub>2.5</sub>, total suspended particles (TSPs) and black smoke.

The following characteristics were reported for each paper: authors, location and year of publication; study population; study design and study period (including both the enrolment and the follow-up period, if it was required by the study design); exposure assessment, including the method employed to assess levels, the mean concentration of pollutants and their exposure metrics; traffic exposure indicators (such as distance from the nearest high-traffic road and traffic density); and effect estimates of both total and specific-cause mortality.

### Meta-analysis

Before pooling data, we converted the effect estimates related to NO<sub>x</sub> into NO<sub>2</sub> effects, using a conversion factor of 0.75 [6]. The NO<sub>2</sub> concentrations expressed in parts per billion were converted into micrograms per cubic metre; we used a conversion factor of 1.88 (at 25°C and 1013 mb) for both NO<sub>2</sub> and NO<sub>x</sub>. The effects related to TSP were converted into PM<sub>10</sub> effects, using a factor of 0.75 [7], and the effects related to PM<sub>10</sub> were converted into PM<sub>2.5</sub> effects, using a factor of 0.7 [8]. Diesel particulate matter and black smoke were analysed as indicators of PM<sub>2.5</sub> [9]. In addition, the effects expressed as interquartile (or quintile or percentile) differences were converted into effects of a 10-µg·m<sup>-3</sup> increase of each pollutant.

We used hazard ratios, odds ratios and relative risks (RRs) of mortality in a random-effects meta-analysis [10] (Stata, version 10; StataCorp, College Station, TX, USA), thus including the risk estimates in the pooled analysis irrespective of the study design. The risk estimates and 95% confidence intervals from each study were reported, having been adjusted for all the factors the authors assessed as confounders. The standard error of the effect was calculated from the risk estimates and the confidence intervals ( $SE = (\ln RR - \ln \text{lowest limit CI})/1.96$  or  $SE = (\ln \text{highest limit CI} - \ln RR)/1.96$ ). The random pooled effects were reported as hazard ratios, as most studies used Cox's survival analysis. We assessed heterogeneity across studies by using the Chi-squared test (Cochran's Q) and inconsistency (I<sup>2</sup>) [11], which represents the proportion of total variation in effect estimates due to heterogeneity across the studies. Finally, we stratified the results by geographical area (Asia, North America and Europe).

To compare the relative effects of NO<sub>2</sub> and PM<sub>2.5</sub>, we carried out a meta-analysis using the interquartile range (IQR) as the exposure metric instead of the fixed increment (10 µg·m<sup>-3</sup>). We included only studies where the IQRs were available or could be derived by using the mean concentrations and their standard deviations. The pooled estimate was obtained for a median IQR of all the single IQRs from those reported or specifically estimated.

### Results

Our initial search led to the selection of a total of 180 articles that were seen to deal with NO<sub>2</sub> (or NO<sub>x</sub>) exposure. We excluded 146 articles on the basis of their titles and abstracts: nine reviews, 12 articles that did not analyse original data, two methodological studies, eight with study designs that made it impossible to adjust for individual confounders, 33 articles that did not assess health effects or human outcomes, 46 articles dealing with short-term effects, 26 articles with long-term effects other than mortality, one article studying only lung cancer mortality and nine articles with a mean exposure to air pollution <1 year. Thereafter, from the 34 studies that had been identified as warranting reading in full, we selected 23 studies [12–34] that assessed particulate matter effects in addition to NO<sub>2</sub> or NO<sub>x</sub> effects. All the selected studies and their characteristics are reported in detail in online supplementary table S1. The 11 excluded studies are listed in table S2.

14 studies [12, 13, 17, 19–24, 26, 30–32, 34] evaluated natural or total mortality; 17 studies [12, 13, 15, 17–20, 22, 23, 25–29, 32–34] considered cardiovascular mortality (including four studies [13, 23, 32, 34] assessing cardiopulmonary mortality); 13 studies considered respiratory mortality [12–14, 16, 17, 19, 20, 22, 23, 26, 28, 32, 34] (including the four with cardiopulmonary mortality as a single outcome [13, 23, 32, 34], and a further one [14] that assessed lung cancer and respiratory mortality as a single outcome). Only 10 studies [12, 13, 17, 19, 20, 22, 23, 26, 32, 34] evaluated both total and cause-specific mortality, although data were not always exhaustively reported. There were 21 cohort studies [12–24, 26–28, 30–34] and two case-control studies [25, 29].

Cohort studies involved adults of both sexes but one study selected only adult males [20] and four selected only adult females [13, 19, 27, 32], and two further articles [28, 33] studied both males and females but separately. Among the other studies, one studied only females [29]. Five studies focused on specific at-risk groups: patients with stroke [21], respiratory diseases [22], hypertension [24] and first myocardial infarction [25, 29].

Several confounders were assessed in each article. Sex, age and social class (identified by different indicators such as education, deprivation index, occupation, area-level socioeconomic position (SEP) or income) were included in most studies. Only DONG *et al.* [14], KATANODA *et al.* [16] and LIPPERT *et al.* [24] included no

SEP indicator in their final analysis. Habitual smoking was frequently adjusted for [15–17, 21, 26, 27, 32, 33], whereas comorbidities were rarely assessed [12, 18, 21].

Asia was represented by four studies (one from Japan [16] and three from China [14, 15, 17]), North America contributed nine studies (two from Canada [18, 22] and seven from the USA [19, 20, 23, 24, 30, 31, 33]) and Europe contributed 10 studies [12, 13, 21, 25–29, 32, 34].

NO<sub>2</sub> was a main exposure in almost all studies, but two [17, 24] used NO<sub>x</sub>. The exposure metric was mostly expressed in micrograms of NO<sub>2</sub> per cubic metre, but one study from Asia [16], one from Canada [22] and all seven studies from the USA [19, 20, 23, 24, 30, 31, 33] reported the mean levels of NO<sub>2</sub> in parts per billion. The unit increase of NO<sub>2</sub> was usually reported (16 studies from all the geographic areas) as interquartile or centile range rather than as per 10 µg·m<sup>-3</sup> [12, 13, 18–20, 22–25, 26–29, 31–33].

The mean yearly level of NO<sub>2</sub> was 41.6 µg·m<sup>-3</sup> in Asia, 42.2 µg·m<sup>-3</sup> in North America and 36.2 µg·m<sup>-3</sup> in Europe.

Particulate matter was studied for the most part as PM<sub>10</sub> (11 studies) [13–15, 19–21, 25, 27–29, 32] with the effect estimated per 10 µg·m<sup>-3</sup> (four studies [14, 15, 19, 21]) or IQR, expressed in micrograms per cubic metre. PM<sub>2.5</sub> was studied in 11 cases [12, 16, 18, 22–24, 26, 30, 31, 33, 34] with exposure expressed most frequently as an IQR increase of concentrations (six studies [12, 18, 22, 23, 31, 33]). TSPs (expressed per 10 µg·m<sup>-3</sup>) was the particle metric in one study [17]. The mean yearly level of PM<sub>2.5</sub> was 87.4 µg·m<sup>-3</sup> in Asia, 14.8 µg·m<sup>-3</sup> in North America and 25.4 µg·m<sup>-3</sup> in Europe.

The correlation between NO<sub>2</sub> (or NO<sub>x</sub>) and PM<sub>10</sub> was reported in eight studies out of 11, with values ranging from 0.5 [13] to 0.9 [14, 15, 29]. The correlation between NO<sub>2</sub> and PM<sub>2.5</sub> was reported in nine studies out of 11, with values ranging from 0.3 in the Japanese study [16] and in the Californian (USA) study [33] to 0.88 in the Norwegian study [28]. The study using only TSPs [17] did not indicate the correlation with NO<sub>2</sub>.

Traffic exposure indicators were reported in nine publications. Two evaluated proximity to a road with heavy traffic and traffic density [12, 26], the studies in Toronto, Canada [22] and in Germany (the Study on the Influence of Air Pollution on Lung, Inflammation and Aging) [13, 27, 32] investigated only proximity to traffic, and the US Veterans Affairs studies [24, 30, 31] evaluated traffic density only.

We included 19 studies in the meta-analysis. Four of the 23 included in the systematic review have been further excluded from the meta-analysis, as three of them reported more complete analyses 3 years later [29–31] and one other [14] reported mortality only for respiratory diseases and lung cancer as a single outcome. In contrast, two of the included papers [28, 33] carried out separate analyses for males and females, thus producing 21 effect estimates actually analysed.

TABLE 1 Pooled<sup>#</sup> effects of nitrogen dioxide (NO<sub>2</sub>) and particulate matter <2.5 µm in diameter (PM<sub>2.5</sub>) [per 10 µg·m<sup>-3</sup>] on natural and cause-specific mortality by region of the world

	Total or natural mortality			Cardiovascular mortality			Respiratory mortality		
	Studies n	RR (95% CI)	I <sup>2</sup> %	Studies n	RR (95% CI)	I <sup>2</sup> %	Studies n	RR (95% CI)	I <sup>2</sup> %
<b>NO<sub>2</sub></b>									
All countries	12	1.041 (1.019–1.064)	89	18 <sup>†,+</sup>	1.133 (1.088–1.180)	98	9 <sup>+,§,f</sup>	1.024 (1.017–1.032)	0
Asia	1	1.020 (1.000–1.030)		2	1.588 (0.675–3.740)	99	2	1.023 (1.010–1.036)	47
North America	5	1.027 (0.987–1.069)	95	7	1.031 (0.999–1.065)	67	3	1.005 (0.975–1.035)	0
Europe	6	1.066 (1.029–1.104)	72	9	1.059 (1.032–1.086)	79	4	1.029 (1.013–1.045)	0
<b>PM<sub>2.5</sub></b>									
All countries	11 <sup>###</sup>	1.045 (1.007–1.088)	87	17 <sup>†,+,###</sup>	1.196 (1.091–1.31)	98	8 <sup>+,§,f,###</sup>	1.050 (1.009–1.094)	61
Asia	1	1.000 (0.980–1.020)		2	1.380 (0.761–2.502)	99	2	1.034 (0.943–1.134)	50
North America	4	1.047 (1.035–1.106)	83	6	1.047 (0.992–1.106)	71	2	1.046 (0.990–1.104)	0
Europe	6	1.071 (1.021–1.124)	62	9	1.188 (1.091–1.295)	42	4	1.075 (1.009–1.146)	40

RR: relative risk; I<sup>2</sup>: inconsistency. <sup>#</sup>: results from random-effects meta-analyses. <sup>†</sup>: two studies (one from North America [33] and one from Europe [28]) were included twice with separate groups of males and females. <sup>+</sup>: four studies (one from America [23] and three from Europe [13, 32, 34]) estimated cardiopulmonary mortality as a whole; they were included in the pooled cardiovascular mortality estimate and excluded from the pooled respiratory mortality estimate. <sup>§</sup>: one study from China [14] was excluded because it estimated lung cancer together with respiratory mortality. <sup>f</sup>: one study from Europe [28] was included twice with separate estimates for males and females. <sup>###</sup>: one study from the USA [22] could be included because it did not present particulate matter effect estimates.




FIGURE 1 Relative risks (RR) of natural mortality with increasing chronic exposure to nitrogen dioxide (NO<sub>2</sub>). df: degrees of freedom; I<sup>2</sup>: inconsistency.

The pooled estimate of natural/total mortality was performed for 12 studies [12, 13, 17, 19–24, 26, 32, 34], the pooled estimate of cardiovascular mortality made use of 18 effect estimates [12, 13, 15, 17–20, 22, 23, 25–28, 32, 33, 34] (as two studies analysed males and females separately), the meta-analytic estimate of respiratory mortality included nine effect estimates [12, 16, 17, 19, 20, 22, 26, 28] (as one study analysed males and females separately [28]).

The pooled estimate of NO<sub>2</sub> effects on natural/total mortality (table 1 and fig. 1) was RR 1.04 (95% CI 1.02–1.06) per 10 µg·m<sup>-3</sup> NO<sub>2</sub> and the corresponding effect of PM<sub>2.5</sub> was RR 1.05 (95% CI 1.01–1.09) per 10 µg·m<sup>-3</sup> PM<sub>2.5</sub>. However, there was high heterogeneity across the studies in North America: the NO<sub>2</sub> effects were not statistically significant while the effects of PM<sub>2.5</sub> were larger and statistically significant (in spite of the fact that the levels of PM<sub>2.5</sub> observed there were the lowest we found). The greatest effect on natural/total mortality was observed in Europe for both NO<sub>2</sub> and PM<sub>2.5</sub> but heterogeneity observed across the studies was still high. It should be noticed that a part of this heterogeneity could be explained by just one study [21] on stroke patients.

The pooled estimate of the NO<sub>2</sub> effect (table 1 and fig. 2) on cardiovascular mortality was RR 1.13 (95% CI 1.09–1.18), while the effect of PM<sub>2.5</sub> was RR 1.20 (95% CI 1.09–1.31), per 10 µg·m<sup>-3</sup> of each pollutant. In Asia, the effects of both NO<sub>2</sub> and PM<sub>2.5</sub> were greater than those in North America and Europe. Notably, the results were affected by high heterogeneity in all areas. In Asia, where the overall NO<sub>2</sub> estimate did not attain statistical significance (and heterogeneity showed values near 99%), one study [15] provided very high effect estimates, much greater than for the other studies. In North America, the study in Toronto [22], carried out on patients from a respiratory clinic, provided effects on cardiovascular mortality as high as 64% for NO<sub>2</sub>, in contrast with a mean increase of 1% in the other studies.

To better evaluate the heterogeneity of the pooled effect estimates of NO<sub>2</sub> on total and cardiovascular mortality, we conducted subgroup analyses considering studies not involving at-risk groups, *i.e.* excluding the studies by MAHESWARAN *et al.* [21], JERRET *et al.* [22], LIPPERT *et al.* [24] and ROSENLUND *et al.* [25], and studies with better exposure assessment (land use regression (LUR), dispersion models or other methods at the address level) [12, 18–22, 25, 26, 28]. The heterogeneity of the effects generally remained in these subgroups when they were considered separately (table S3). However, when we restricted our analysis to studies conducted in the general population (not on at-risk groups) and with a better exposure assessment, the heterogeneity for cardiovascular mortality decreased (p=0.690 and I<sup>2</sup>=0%, based on seven studies) corresponding to an effect estimate of 1.03 for NO<sub>2</sub>.




FIGURE 2 Relative risks (RRs) of cardiovascular (CV) mortality with increasing chronic exposure to nitrogen dioxide (NO<sub>2</sub>). df: degrees of freedom; I<sup>2</sup>: inconsistency.




FIGURE 3 Relative risks (RRs) of respiratory mortality with increasing chronic exposure to nitrogen dioxide (NO<sub>2</sub>). df: degrees of freedom; I<sup>2</sup>: inconsistency.

TABLE 2 Pooled<sup>#</sup> effects of nitrogen dioxide (NO<sub>2</sub>) and particulate matter <2.5 µm in diameter (PM<sub>2.5</sub>) on natural and specific-cause mortality

	Total or natural mortality				Cardiovascular mortality				Respiratory mortality			
	Increment µg·m <sup>-3</sup>	Studies n	RR (95% CI)	I <sup>2</sup> %	Increment µg·m <sup>-3</sup>	Studies n	RR (95% CI)	I <sup>2</sup> %	Increment µg·m <sup>-3</sup>	Studies n	RR (95% CI)	I <sup>2</sup> %
<b>NO<sub>2</sub></b>	10	10 <sup>¶</sup>	1.040 (1.015–1.065)	91	10	15 <sup>†,§,f</sup>	1.152 (1.094–1.213)	98	10	7 <sup>##,¶¶</sup>	1.024 (1.010–1.038)	0
	14.6		1.059 (1.022–1.096)		17.9		1.288 (1.174–1.413)		15		1.036 (1.015–1.058)	
<b>PM<sub>2.5</sub></b>	10	9 <sup>¶,++</sup>	1.050 (1.024–1.078)	78	10	14 <sup>†,§,f,¶¶</sup>	1.228 (1.084–1.39)	98	10	6 <sup>##,¶¶,++</sup>	1.062 (1.022–1.104)	11
	5.8		1.029 (1.014–1.045)		7		1.155 (1.058–1.259)		7		1.043 (1.015–1.072)	

RR: relative risk; I<sup>2</sup>: inconsistency. <sup>¶</sup>: random estimates. <sup>¶¶</sup>: two studies [17, 34] were excluded as they did not give interquartile range (IQR) estimates or dispersion parameters to estimate them. <sup>†</sup>: three studies [17, 25, 34] were excluded as they did not give IQR estimates or dispersion parameters to estimate them. <sup>‡</sup>: two studies [28, 33] were included twice with separate groups of males and females. <sup>§</sup>: two studies from Europe [13, 32] estimated cardiopulmonary mortality as a whole; they were included in the pooled, cardiovascular mortality estimate and excluded from the respiratory mortality pooled estimate. <sup>¶</sup>: three studies [16, 17, 34] were excluded as they did not give IQRs or dispersion parameters to estimate them. <sup>¶¶</sup>: one study from Europe [28] was included twice with separate groups of males and females. <sup>++</sup>: one study from Canada [22] could be included as it did not present the particulate matter effect estimates.

The pooled estimate of NO<sub>2</sub> effects (table 1 and fig. 3) on respiratory mortality was RR 1.02 (95% CI 1.02–1.03) while the PM<sub>2.5</sub> effect was RR 1.05 (95% CI 1.01–1.09). The results for NO<sub>2</sub> were homogeneous across the studies. The large effect of PM<sub>2.5</sub> on respiratory mortality was notable in Europe, where an effect of 8% was detected with a heterogeneity as high as 40%.

The results of the pooled estimates using IQRs as the exposure metric are presented in table 2. The number of studies with available estimates is slightly lower than for the analysis using a fixed increment, as four of them [16, 17, 25, 34] did not provide IQR data or figures to estimate them. The median IQRs were different for the outcomes considered and the variability of NO<sub>2</sub> levels was greater than for PM<sub>2.5</sub> (e.g. 14.1 µg·m<sup>-3</sup> for NO<sub>2</sub> and 5.4 µg·m<sup>-3</sup> for PM<sub>2.5</sub> in natural/total mortality studies). The estimates based on IQRs showed greater effects of NO<sub>2</sub> than of PM<sub>2.5</sub> on total mortality (6% versus 3% for PM<sub>2.5</sub>) and on cardiovascular mortality (29% versus 16% for PM<sub>2.5</sub>). The effects were similar for respiratory mortality (4% for both NO<sub>2</sub> and PM<sub>2.5</sub>).

The results of the multipollutant analyses (as assessed in the original papers) are reported in table S4. Only seven studies [12, 17, 18, 20, 22, 24, 32] among those included in the meta-analysis performed bipollutant analyses, including those by GEHRING *et al.* [32], JERRETT *et al.* [22] and LIPPERT *et al.* [24], who analysed the NO<sub>2</sub> effects only with a traffic indicator. CAO *et al.* [17] in Asia and CESARONI *et al.* [12] in Europe found no change in the effects of NO<sub>2</sub> on total mortality when it was analysed together with particulate matter, whereas the reduced effect observed by HART *et al.* [20] in the USA relates to a model including three pollutants (NO<sub>2</sub>, PM<sub>10</sub> and sulfur dioxide). Among the three studies that analysed NO<sub>2</sub> and particulate matter effects on cardiovascular mortality [17, 18, 20], two [18, 20] found independent effects of NO<sub>2</sub>. Three studies analysed NO<sub>2</sub> effects with a traffic indicator: those by LIPPERT *et al.* [24] in the USA and JERRETT *et al.* [22] in Toronto found reduced effects of NO<sub>2</sub> on total and cardiovascular mortality, but no change was reported in the European study [32].

## Discussion

We found similar risk estimates for total mortality in studies investigating the long-term effects of both NO<sub>2</sub> and PM<sub>2.5</sub> (4% versus 5% increase, respectively) using an exposure metric of 10 µg·m<sup>-3</sup>. In Europe, there was a 7% increase in total mortality for both NO<sub>2</sub> and fine particles. HOEK *et al.* [5], in their recent review, found a worldwide pooled estimate of 5.5% (95% CI 3.1–8.0%) for NO<sub>2</sub>; their study, unlike the present one, included estimates from studies that did not analyse particles. We found greater effects of PM<sub>2.5</sub> than of NO<sub>2</sub> for cardiovascular (20% versus 13%) and respiratory (5% versus 2%) mortality, per 10 µg·m<sup>-3</sup> of pollutants. Per IQR, estimates of cardiovascular mortality were larger for NO<sub>2</sub> than for PM<sub>2.5</sub> (29% versus 16%). In the recent review by HOEK *et al.* [5], NO<sub>2</sub> effects ranging from 3% to 36% per 10 µg·m<sup>-3</sup> have been reported for cardiovascular mortality in European cohorts as well as an effect of 12% for respiratory mortality. All our estimates were rather heterogeneous, with the sole exception of respiratory mortality. In the few studies with bipollutant models, the effects of NO<sub>2</sub> and particles (of different sizes) seemed independent.

The comparison of studies carried out in worldwide geographical areas is beset by many challenges. The methods used to assess exposure play an important role. The NO<sub>2</sub> levels observed in the USA, Asia and Europe are very similar. In contrast, PM<sub>2.5</sub> levels are lower in the USA than in Europe, and both are much lower in Asia. The methods used in assessing exposure (such as dispersion modelling, LUR models and inverse distance weighting) as well as the methods used in pollution monitoring (such as the number and location of fixed monitors as well as the daily sampling intervals) could all influence the quality of the exposure assessment causing a possible differential misclassification. However, as lower levels of PM<sub>2.5</sub> in the USA produced effects on total mortality comparable to those observed in Europe, a different toxicity of the fine particle components between areas could also play a role.

The length of the exposure (or modelling) period was not always taken sufficiently into consideration. This is an important drawback when risk estimates for long-term mortality are to be compared. The length of exposure assessment ranged from 1 [21, 23] to 12 years [15] when reported as measured levels of pollutants, and from 2 to 40 years when estimated by means of models (mainly dispersion or LUR models). In addition, length of exposure is mostly assessed on the basis of length of residence, assuming that the pollution levels monitored in a shorter time than residence period represents the real exposure of the whole residence period. Only a few investigations have addressed the long-term stability of the spatial contrasts in the exposures used in the epidemiological analyses [35, 36]

Latency differs among studies, often not consistently with the study design. Three studies [15, 17, 19] had an overlap between the exposure and the follow-up periods; others started the follow-up in the same year the pollutant exposure was assessed [24, 28], although they prolonged the follow-up for up to 30 years. In a few studies [12, 20, 21, 34] exposure was assessed in a few years included within the follow-up or even after the follow-up [22]. Finally, eight studies [16, 18, 23, 25, 26, 27, 32, 33] carried out a follow-up from at least



1 year after the assessed exposure for up to 6–20 years thereafter. Therefore, the differences in assessing the temporal relationship between exposure and outcome across the studies represent a possible challenge for the interpretation of the results. Doubts could also arise when the exposure has been assessed after starting follow-up, since strong assumptions were necessary about the length of residence and the corresponding levels of pollutants.

Some methodological choices in carrying out the meta-analysis need to be discussed. The first relevant point for the interpretation of the results is the reliability of the meta-analytic estimates by geographic area. The European and North American estimates for total and cardiovascular mortality, as well as the European estimates for respiratory mortality, are more reliable than Asian estimates because at least four articles were included. However, the heterogeneity across the studies affects the reliability [10, 37] of the estimates of total and cardiovascular mortality, in all areas and for both pollutants. The sole exception is the effect of NO<sub>2</sub> on respiratory mortality in both Europe and the USA (with three studies). It should be noted that the heterogeneity for cardiovascular mortality was strongly reduced when we restricted to studies with a better quality of exposure assessment and evaluating the entire population and not at at-risk groups [38].

A second methodological point for the interpretation of results is related to the pollutant exposure metric for analysing the effects of different pollutants. Using a fixed increase of 10 µg·m<sup>-3</sup> in pollutant levels makes it possible to compare the effects of a single pollutant across different studies and different countries. In contrast, if one wishes to compare the effects of two or more pollutants, one needs another metric that takes into account the different distributions of pollutant levels. A pollutant with a broader exposure distribution will show smaller effect estimates per unit increase than a pollutant with a less wide exposure distribution in the same population. The additional meta-analyses we performed using the IQRs of NO<sub>2</sub> and PM<sub>2.5</sub> as the exposure metric show that the NO<sub>2</sub> effects on mortality are larger than those of PM<sub>2.5</sub>, at least for total and cardiovascular mortality.

There is obviously a need for caution in drawing conclusions about the independence of NO<sub>2</sub> effects from PM<sub>2.5</sub> effects from the multipollutant models. First, not all countries were included (*e.g.* Asia was less represented in this analysis). Second, the high correlation between NO<sub>2</sub> and PM<sub>2.5</sub> (around 0.7–0.8) in these studies still suggests the possibility that the NO<sub>2</sub> effects could be due in part to confounding from particulate matter. Third, uncertainty is also due to the limited number of bipollutant estimates available. It should be noted, however, that only minimal difference between the single-pollutant and the multipollutant results for NO<sub>2</sub> were found.

Finally, although this study cannot respond exhaustively to the causality question about NO<sub>2</sub>, given that it was a meta-analysis, it contributes to the scientific debate on this topic because it assesses the respective role of NO<sub>2</sub> and PM<sub>2.5</sub> as they emerge from prospective studies [37] and provides a pooled effect estimate to be used for future impact health assessment.

In conclusion, the magnitude of the long-term effects of NO<sub>2</sub> on mortality is at least as important as that of PM<sub>2.5</sub>. These results hold when using either 10 µg·m<sup>-3</sup> or IQR as the metric of choice. The results of the multipollutant models suggest that the role of NO<sub>2</sub> is independent of that of particles. All these elements may be useful when discussing the causality issue for NO<sub>2</sub>. Moreover, NO<sub>2</sub> is the only widely regulated pollutant (apart from carbon monoxide) that indicates exposure to combustion pollution. Health impact assessments relying only on PM<sub>2.5</sub>, and not considering NO<sub>2</sub>, would be neglecting an important source of the adverse effects of today's pollution mixture.

## Acknowledgements

We thank K. Christenfeld (freelance medical editor, Rome, Italy) for editorial revision and S. Ricci (Dept of Epidemiology, Regional Health System, Lazio Region, Rome, Italy) for her help with the figures.

## References

- 1 WHO Europe. Air quality guidelines for particulate matter, ozone, nitrogen dioxide and sulfur dioxide. Global update 2005. Geneva, World Health Organization, 2006.
- 2 Eisner MD, Anthonisen N, Coultas D, *et al.* An official American Thoracic Society public policy statement: novel risk factors and the global burden of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2010; 182: 693–718.
- 3 HEI Panel on the Health Effects of Traffic-Related Air Pollution. Traffic-related air pollution: a critical review of the literature on emissions, exposure, and health effects. HEI Special Report 17. Boston, Health Effects Institute, 2010.
- 4 WHO Regional Office for Europe. Review of evidence on health aspects of air pollution – REVIHAAP project: technical report. [www.euro.who.int/en/what-we-do/health-topics/environment-and-health/air-quality/publications/2013/](http://www.euro.who.int/en/what-we-do/health-topics/environment-and-health/air-quality/publications/2013/) Date last updated: 2013.
- 5 Hoek G, Krishnan RM, Beelen R, *et al.* Long-term air pollution exposure and cardio-respiratory mortality: a review. *Environ Res* 2013; 12: 43.

- 6 Environmental Protection Agency. Revision to the guideline on air quality models: adoption of a preferred general purpose (flat and complex terrain) dispersion model and other revisions. *Fed Register* 2005; 70: 216.
- 7 Le Tertre A, Medina S, Samoli E, *et al.* Short-term effects of particulate air pollution on cardiovascular diseases in eight European cities. *J Epidemiol Community Health* 2002; 56: 773–779.
- 8 Peters A, Breitner S, Cyrus J, *et al.* The Influence of Improved Air Quality on Mortality Risks in Erfurt, Germany. Appendix B. Correlations and Ratios between Pollutants on an Annual Basis. HEI Research Report 137. Boston, Health Effects Institute, 2009.
- 9 Brunekreef B, Beelen R, Hoek G, *et al.* Effects of Long-Term Exposure to Traffic-Related Air Pollution on Respiratory and Cardiovascular Mortality in the Netherlands: The NLCS-AIR Study. HEI Research Report 139. Boston, Health Effects Institute, 2009.
- 10 Egger M, Smith GD, Altman D. Systematic Reviews in Health Care: Meta-Analysis in Context. London, BMJ Publishing Group, 2001.
- 11 Higgins JPT, Thompson SG, Deeks JJ, Altman DG Measuring inconsistency in meta-analyses, *BMJ* 2003; 327: 557–560.
- 12 Cesaroni G, Badaloni C, Gariazzo C, *et al.* Long-term exposure to urban air pollution and mortality in a cohort of more than a million adults in Rome. *Environ Health Perspect* 2013; 121: 324–331.
- 13 Heinrich J, Thiering E, Rzehak P, *et al.* Long-term exposure to NO<sub>2</sub> and PM<sub>10</sub> and all-cause and cause-specific mortality in a prospective cohort of females. *Occup Environ Med*. 2013; 70: 179–186.
- 14 Dong GH, Zhang P, Sun B, *et al.* Long-Term exposure to ambient air pollution and respiratory disease mortality in Shenyang, China: a 12-year population-based retrospective cohort study. *Respiration* 2012; 84: 360–368.
- 15 Zhang P, Dong G, Sun B, *et al.* Long-term exposure to ambient air pollution and mortality due to cardiovascular disease and cerebrovascular disease in Shenyang, China. *PLoS One* 2011; 6: e20827.
- 16 Katanoda K, Sobue T, Satoh H, *et al.* An association between long-term exposure to ambient air pollution and mortality from lung cancer and respiratory diseases in Japan. *J Epidemiol* 2011; 21: 132–143.
- 17 Cao J, Yang C, Li J, *et al.* Association between long-term exposure to outdoor air pollution and mortality in China: a cohort study. *J Hazard Mater* 2011; 186: 1594–1600.
- 18 Gan WQ, Koehoorn M, Davies HW, *et al.* Long-term exposure to traffic-related air pollution and the risk of coronary heart disease hospitalization and mortality. *Environ Health Perspect* 2011; 119: 501–507.
- 19 Lipsett MJ, Ostro BD, Reynolds P, *et al.* Long-term exposure to air pollution and cardiorespiratory disease in the California teachers study cohort. *Am J Respir Crit Care Med* 2011; 184: 828–835.
- 20 Hart JE, Garshick E, Dockery DW, *et al.* Long-term ambient multipollutant exposures and mortality. *Am J Respir Crit Care Med* 2011; 183: 73–78.
- 21 Maheswaran R, Pearson T, Smeeton NC, *et al.* Impact of outdoor air pollution on survival after stroke: population-based cohort study. *Stroke* 2010; 41: 869–877.
- 22 Jerrett M, Finkelstein MM, Brook JR, *et al.* A cohort study of traffic-related air pollution and mortality in Toronto, Ontario, Canada. *Environ Health Perspect* 2009; 117: 772–777.
- 23 Krewski D, Jerrett M, Burnett RT, *et al.* Extended follow-up and spatial analysis of the American Cancer Society study linking particulate air pollution and mortality. Boston, Health Effects Institute, 2009.
- 24 Lipfert FW, Wyzga RE, Baty JD, *et al.* Air pollution and survival within the Washington University–EPRI Veterans cohort: risks based on modeled estimates of ambient levels of hazardous and criteria air pollutants. *J Air Waste Manage Assoc* 2009; 59: 473–489.
- 25 Rosenlund M, Bellander T, Nordquist T, *et al.* Traffic-generated air pollution and myocardial infarction. *Epidemiology* 2009; 20: 265–271.
- 26 Beelen R, Hoek G, van den Brandt PA, *et al.* Long-term effects of traffic-related air pollution on mortality in a Dutch cohort (NLCS-AIR Study). *Environ Health Perspect* 2008; 116: 196–202.
- 27 Schikowski T, Sugiri D, Ranft U, *et al.* Does respiratory health contribute to the effects of long-term air pollution exposure on cardiovascular mortality? *Respir Res* 2007; 8: 20.
- 28 Naess O, Nafstad P, Aamodt G, *et al.* Relation between concentration of air pollution and cause-specific mortality: four-year exposures to nitrogen dioxide and particulate matter pollutants in 470 neighbourhoods in Oslo, Norway. *Am J Epidemiol* 2007; 165: 435–443.
- 29 Rosenlund M, Berglund N, Pershagen G, *et al.* Long-term exposure to urban air pollution and myocardial infarction. *Epidemiology* 2006; 17: 383–390.
- 30 Lipfert FW, Baty JD, Miller JP, *et al.* PM<sub>2.5</sub> constituents and related air quality variables as predictors of survival in a cohort of U.S. military veterans. *Inhal Toxicol* 2006; 18: 645–657.
- 31 Lipfert FW, Wyzga RE, Baty JD, *et al.* Traffic density as a surrogate measure of environmental exposures in studies of air pollution health effects: long-term mortality in a cohort of US veterans. *Atmospheric Environment* 2006; 40: 154–169.
- 32 Gehring U, Heinrich J, Krämer U, *et al.* Long-term exposure to ambient air pollution and cardiopulmonary mortality in females. *Epidemiology* 2006; 17: 545–551.
- 33 Chen LH, Knutsen SF, Shavlik D, *et al.* The association between fatal coronary heart disease and ambient particulate air pollution: are females at greater risk? *Environ Health Perspect* 2005; 113: 1723–1729.
- 34 Filleul L, Rondeau V, Vandentorren S, *et al.* Twenty five year mortality and air pollution: results from the French PAARC survey. *Occup Environ Med* 2005; 62: 453–460.
- 35 Eeftens M, Beelen R, Fischer P, *et al.* Stability of measured and modelled spatial contrasts in NO<sub>2</sub> over time. *Occup Environ Med* 2011; 68: 765–770.
- 36 Cesaroni G, Porta D, Badaloni C, *et al.* Nitrogen dioxide levels estimated from land use regression models several years apart and association with mortality in a large cohort study. *Environ Health* 2012; 11: 1.
- 37 Weed DL. Interpreting epidemiological evidence: how meta-analysis and causal inference methods are related. *Int J Epidemiol* 2000; 29: 387–390.
- 38 Brookes ST, Whitley E, Peters TJ, *et al.* Subgroup analyses in randomized controlled trials: quantifying the risks of false-positives and false-negatives. *Health Technol Assess* 2001; 5: 33.